IBDEI1XP ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30896,0)
 ;;=N03.1^^123^1597^17
 ;;^UTILITY(U,$J,358.3,30896,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30896,1,3,0)
 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,30896,1,4,0)
 ;;=4^N03.1
 ;;^UTILITY(U,$J,358.3,30896,2)
 ;;=^5015522
 ;;^UTILITY(U,$J,358.3,30897,0)
 ;;=N03.2^^123^1597^14
 ;;^UTILITY(U,$J,358.3,30897,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30897,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,30897,1,4,0)
 ;;=4^N03.2
 ;;^UTILITY(U,$J,358.3,30897,2)
 ;;=^5015523
 ;;^UTILITY(U,$J,358.3,30898,0)
 ;;=N03.3^^123^1597^15
 ;;^UTILITY(U,$J,358.3,30898,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30898,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,30898,1,4,0)
 ;;=4^N03.3
 ;;^UTILITY(U,$J,358.3,30898,2)
 ;;=^5015524
 ;;^UTILITY(U,$J,358.3,30899,0)
 ;;=N03.4^^123^1597^13
 ;;^UTILITY(U,$J,358.3,30899,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30899,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,30899,1,4,0)
 ;;=4^N03.4
 ;;^UTILITY(U,$J,358.3,30899,2)
 ;;=^5015525
 ;;^UTILITY(U,$J,358.3,30900,0)
 ;;=N03.5^^123^1597^16
 ;;^UTILITY(U,$J,358.3,30900,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30900,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,30900,1,4,0)
 ;;=4^N03.5
 ;;^UTILITY(U,$J,358.3,30900,2)
 ;;=^5015526
 ;;^UTILITY(U,$J,358.3,30901,0)
 ;;=N03.6^^123^1597^11
 ;;^UTILITY(U,$J,358.3,30901,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30901,1,3,0)
 ;;=3^Chr nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,30901,1,4,0)
 ;;=4^N03.6
 ;;^UTILITY(U,$J,358.3,30901,2)
 ;;=^5015527
 ;;^UTILITY(U,$J,358.3,30902,0)
 ;;=N03.7^^123^1597^12
 ;;^UTILITY(U,$J,358.3,30902,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30902,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,30902,1,4,0)
 ;;=4^N03.7
 ;;^UTILITY(U,$J,358.3,30902,2)
 ;;=^5015528
 ;;^UTILITY(U,$J,358.3,30903,0)
 ;;=N03.8^^123^1597^19
 ;;^UTILITY(U,$J,358.3,30903,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30903,1,3,0)
 ;;=3^Chr nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,30903,1,4,0)
 ;;=4^N03.8
 ;;^UTILITY(U,$J,358.3,30903,2)
 ;;=^5015529
 ;;^UTILITY(U,$J,358.3,30904,0)
 ;;=N03.9^^123^1597^20
 ;;^UTILITY(U,$J,358.3,30904,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30904,1,3,0)
 ;;=3^Chr nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,30904,1,4,0)
 ;;=4^N03.9
 ;;^UTILITY(U,$J,358.3,30904,2)
 ;;=^5015530
 ;;^UTILITY(U,$J,358.3,30905,0)
 ;;=N04.0^^123^1597^59
 ;;^UTILITY(U,$J,358.3,30905,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30905,1,3,0)
 ;;=3^Nephrotic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,30905,1,4,0)
 ;;=4^N04.0
 ;;^UTILITY(U,$J,358.3,30905,2)
 ;;=^5015531
 ;;^UTILITY(U,$J,358.3,30906,0)
 ;;=N04.1^^123^1597^58
 ;;^UTILITY(U,$J,358.3,30906,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30906,1,3,0)
 ;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,30906,1,4,0)
 ;;=4^N04.1
 ;;^UTILITY(U,$J,358.3,30906,2)
 ;;=^5015532
 ;;^UTILITY(U,$J,358.3,30907,0)
 ;;=N04.2^^123^1597^55
 ;;^UTILITY(U,$J,358.3,30907,1,0)
 ;;=^358.31IA^4^2
